secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001658247-26-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion
--------------------------------------------------------------------------------

- PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.
- CHMP adopted positive opinion recommending EU marketing authorization for paltusotine in acromegaly; EC decision pending.
- Seamless Phase 2/3 EQUILIBRIUM study of atumelnant in Cushing's syndrome to start H1 2026; Phase 3 trials for CAH and carcinoid syndrome initiated.
- Full-year 2025 net loss $465.3M; cash used $326.2M, below guidance; cash $1.0B at Dec 31, 2025 (pro forma $1.4B post Jan 2026 offering).
- 2026 GAAP OpEx guidance $600-650M; non-GAAP OpEx $480-520M; R&D and SG&A investments continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/0001658247-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/crnx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer